The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
|Articles|November 2, 2022
Daily Dose: Blood Pressure Control Declined during Early Months of Pandemic
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 1, 2022, we reviewed a study published in Hypertension titled "Changes in blood pressure outcomes among hypertensive individuals during the COVID-19 pandemic: A time series analysis in three US healthcare organizations."
The study
Researchers examined the electronic health records of 137 593 adults with HTN and compared BP outcomes before the pandemic (August 2018-January 2020) with those during the peak of the pandemic (April 2020- January 2021).
During the pandemic, systolic and diastolic BP increased by 1.79 mm Hg and 1.30 mm, respectively, compared with the prepandemic period. Also, the proportion of patients with controlled BP decreased by 3.43 percentage points. The frequency of documented BP readings sharply declined in the early stages of the pandemic, then gradually rebounded later in the pandemic but never returned to the prepandemic baseline. This was partly due to cancellations or postponements of face-to-face office visits.
Clinical implications
"Opportunities to ensure ongoing access to health care with telemedicine and home blood pressure monitoring may mitigate adverse impacts on blood pressure control for future disasters/emergencies," wrote authors.
Click here for the full study review.
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5